RADIOLABELED ACTIVE TARGETING PHARMACEUTICAL COMPOSITION AND THE USE THEREOF

摘要

The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.

主权项

1. A radiolabeled active targeting pharmaceutical composition, comprising:
a bioconjugate, comprising a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein, when the biomolecule is a protein, the biomolecule is further combined with an intercalating agent, and the intercalating agent is 1,4,7,10-Tetraazacyclotetradecane-1,4,7,10-Tetraacetic acid (1,4,7,10-Tetraazacyclotetradecane-N,N′,N″,N′″-Tetraacetic acid, DOTA); and a radionuclide, selected from the group consisting of: indium, iodine, lutetium, rhenium, gallium, yttrium, and technetium.